Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

MindMed (MNMD) Q2 Net Loss Jumps 625%

TheMotleyFool 
0 0 02.08.25
MindMed (MNMD) Q2 Net Loss Jumps 625%
 

Mind Medicine (MindMed) (NASDAQ:MNMD), a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders, reported its second quarter results on July 31, 2025. The company recorded a GAAP EPS loss of $0.50, wider than analyst expectations of $0.38. Operating costs rose sharply, and Net loss (GAAP) surpassed prior-year levels, reflecting significant clinical trial activity. Strong cash reserves provide a funding runway through 2027. The quarter demonstrated continued focus on advancing late-stage clinical programs, despite heightened losses and no short‑term revenue prospects.

Source: Analyst estimates for the quarter provided by FactSet.

MindMed focuses on developing treatments for mental health disorders using psychedelic compounds. Its research centers on product candidates for conditions such as generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD).

Continue reading


Source Fool.com

Electro Power Systems S.A. Stock

Show more
Like: 0
MNMD
Share

Comments

Not a member yet? Sign up for free!